Artificial intelligence in biopharma Germany - Canadian Technology Accelerator

Are you ready to grow your AI-in-(bio)pharma solution to Europe’s largest healthcare market? 
This premier initiative empowers Canadian companies that offer AI-empowered technologies in the following sectors to successfully expand their operations into Germany:

• precision/personalized medicine
• cell & gene therapy
• drug discovery
• orphan drugs

This program offers a unique opportunity for innovative Canadian enterprises to tap into the thriving German market, renowned for its:

• robust healthcare infrastructure
• cutting-edge research facilities
• strong commitment to medical advancements

Germany has emerged as a key player in precision/personalized medicine, cell & gene therapy and drug discovery. The German market demonstrates high growth potential for AI based solutions. This growth is attributable to several factors, including the country's need for healthcare innovation, a strong focus on advanced healthcare infrastructure, and robust research and development activities in the (bio)pharma field. Germany's emphasis on high-quality healthcare and its supportive regulatory environment make it an ideal destination for companies with AI-driven healthcare solutions.

Furthermore, leading pharmaceutical and biotechnology companies are always looking for solutions to accelerate advancements and reduce costs. This canfacilitate your access to the German market.

Upon acceptance, your business will benefit from:

• extensive background intelligence through virtual panels and workshops with dedicated sector experts on market access 
• introduction to norms and regulations, business culture and best practices
• tailored advice from mentors and local industry experts unique to your business needs
• In-market networking opportunities with introductions to key industry stakeholders including:
  • Big Pharma, bio-pharma industry, healthcare institutions and research institutions
  • insurers and payers
  • innovative, like-minded entrepreneurs to share experiences and collaborate

The AI-in-(Bio)Pharma Germany CTA is looking for innovative Canadian companies who:

• have an AI-based or innovative product/solution for:
  • precision/personalized medicine
  • orphan drugs
  • cell & gene therapy
  • drug discovery 
• have a strong interest in expanding their business to Germany  
• are ready to fully commit to participating in the program, including:
  • advisory meetings (virtual)
  • preparatory work
  • kickoff, virtual and in-market programming

The program will offer customized virtual masterclass sessions from July to November 2025 that will require a commitment of about two hours per week. The AI-in-(Bio)Pharma Germany CTA will establish tailored priorities for each company at the beginning of the program to develop your business strategy and advance your objectives for:

• market entry
• investment
• customer acquisition objectives. 

You will participate in:

• advisory meetings
• masterclass sessions
• opening and closing events 
• a one-week in-market visit

This non-equity program is at no cost to Canadian companies beyond any individual travel costs they incur. Companies should plan to spend 5-7 days in Germany for in-person meetings, pitches and events.